Log in to search using one of your social media accounts:


Aug 11 Cardiology News Aug 11 Cardiology News

Statins after stroke, MI definition, dietary sodium, gene editing, and a potential new way to image coronaries are the topics discussed by Dr John Mandrola in this week's podcast.theheart.org on Medscape
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: None News Source Type: news

Related Links:

(MedPage Today) -- Recent developments of interest in cardiovascular medicine
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
CONCLUSION: Oral anticoagulation was significantly underused in NVAF patients in China. Age, sex, concurrent drug usage and disease history were associated factors. Improving warfarin adherence was promising to reduce ischemic stroke risk of NVAF patients. PMID: 29022745 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzymatic inflammatory biomarker primarily bound to low-density lipoprotein cholesterol, is associated with an approximate twofold increased risk of cardiovascular disease and stroke. Despite indications that circulating Lp-PLA2 is sensitive to statins, it remains largely unknown whether statin usage exerts local effects on Lp-PLA2 expression at the site of atheromatous plaque.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
Publication date: Available online 6 October 2017 Source:Canadian Journal of Cardiology Author(s): Lena Rivard, Paul Khairy Atrial fibrillation (AF) and dementia are major health issues, with growing evidence suggesting a consistent association between AF and all forms of dementia. Although dementia and AF share several risk factors, the association appears to be independent of a history of clinical stroke and other comorbidities such as hypertension, heart failure, and diabetes. Proposed mechanisms linking AF to cognitive decline include altered hemodynamics resulting in cerebral hypoperfusion, inflammation, genetic fact...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
I was really excited to see a recent headline that said heart doctors should discuss herbal medicines with their patients. The recommendation came from a study in the Journal of the American College of Cardiology.1 I thought this was a real breakthrough. I thought it meant cardiologists had finally seen the light… Boy, was I wrong… The article said doctors should learn about herbal medicines so they could STOP their patients from using them. You see, supplement use is at an all-time high. About 70% of Americans take them. That’s a lot of people. And Big Pharma would love to capture that market. So they...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Anti-Aging Source Type: news
I’m used to being a target of mainstream medicine. I can’t even count the number of times I’ve been called a “quack.”  Let me give you just one example… For decades I’ve been treating my patients with a proven therapy. The FDA approved it way back in 1953. I use it to help my patients detox from mercury, lead, cadmium and other heavy metals. In fact, more than 100,000 people get this therapy every year in the U.S. But mainstream doctors still laugh at the idea of this treatment and think it’s pure bunk. I’m talking about intravenous (IV) chelation. Even though I...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Anti-Aging Health Heart Health Men's Health Women's Health Source Type: news
Conclusions -Heretofore unknown effects of torcetrapib were revealed in immune and inflammatory functions. A protein-based risk score predicted harm from torcetrapib within just 3 months. A protein-based risk assessment embedded within a large proteomic survey may prove to be useful in the evaluation of therapies to prevent harm to patients. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00134264. PMID: 28974520 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Conclusions -The addition of ezetimibe to simvastatin in patients stabilized after ACS reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. Clinical Trial Registration -URL: http://www.clinicaltrials.gov Unique Identifier: NCT00202878. PMID: 28972004 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo. However, whether combination therapy or statin alone resulted in cardiovascular benefit is uncertain. Therefore, we estimated GFR in 18,015 individuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in individuals with cardiovascular disease and creatinine clearance>30 ml/min) and examined post hoc the relationshi...
Source: Journal of the American Society of Nephrology : JASN - Category: Urology & Nephrology Authors: Tags: Clinical Research Source Type: research
Conclusions There remain opportunities for improving prevention in patients at risk for cardiovascular events. Our study identified certain patient subgroups that may benefit from interventions to enhance medication adherence, particularly by minimizing treatment gaps and discontinuation of statin therapy within the first year of treatment.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cholesterol | Diets | Genetics | Health | Heart | Nutrition | Podcasts | Sodium | Statin Therapy | Stroke